tirzepatide gip glp 1 drops GLP-1 use tripled among non-diabetics, reaching $5.8B in 2022 Renal effects of GLP-1 receptor

J Clin Endocrinol Metab 2022;107:316274

Current drug delivery systems based on Tf modification can achieve selective cellular uptake, cross the blood-brain barrier, limit systemic toxicity, and reverse multidrug resistance

(E(X)-4)(2)-Fc, an effective long-acting GLP-1 receptor agonist, reduces obesity-related inflammation by inhibiting leptin expression

IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis

Respondents reported a strong desire to reduce the pill burden associated with treatment, or to be off medication entirely, for treatments to help resume normal living, such as the ability to eat without restrictions, for treatments with fewer unpleasant side effects (i.e., weight gain, hypoglycemia, gastrointestinal side effects) and which are less physically invasive (i.e., do not require an injection) and for treatments which can normalize/stabilize blood glucose levels, and improve hemoglobin A1c

Rev Endocr Metab Disord 15(3):181187 van Bloemendaal L et al (2014) GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans